Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory J Dore

Showing results (221-230 of 404) with videos related to

Pageof 41
Sort By:
Clinical Microbiology Reviews|June 13, 2025
Bacterial and fungal infections in persons who inject drugsJeffrey Masters, David Goodman-Meza, Danielle Russell, et al.
European Journal of Gastroenterology & Hepatology|July 23, 2014
Delivery of treatment for hepatitis C virus infection in the primary care settingDavid Baker, Maryam Alavi, Amanda Erratt, et al.
AIDS (London, England)|August 24, 2012
Estimating the cost-effectiveness of needle-syringe programs in AustraliaJisoo A Kwon, Jonathan Anderson, Cliff C Kerr, et al.
Frontiers in Neurology|May 17, 2024
Blood brain barrier disruption and glutamatergic excitotoxicity in post-acute sequelae of SARS COV-2 infection cognitive impairment: potential biomarkers and a window into pathogenesisJoga Chaganti, Govinda Poudel, Lucette Adeline Cysique, et al.
Drug and Alcohol Review|August 9, 2023
Evaluating the prevalence of current hepatitis C infection and treatment among Aboriginal and Torres Strait Islander peoples who inject drugs in Australia: The ETHOS engage studySteven Hobday, Heather Valerio, Troy Combo, et al.
Hepatology (Baltimore, Md.)|October 28, 2011
Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infectionJason Grebely, Son Truong Pham, Gail V Matthews, et al.
Plos One|April 18, 2013
Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individualsGail V Matthews, Rachel J Ali, Anchalee Avihingsanon, et al.
Hepatology (Baltimore, Md.)|April 5, 2013
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antiviralsNatasha K Martin, Peter Vickerman, Jason Grebely, et al.
Plos One|November 27, 2013
Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infectionJordan J Feld, Jason Grebely, Gail V Matthews, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|June 23, 2023
Health-related quality of life among people who inject drugs in AustraliaQinglu Cheng, Sahar Bajis, Evan Cunningham, et al.
Pageof 41

Showing results (221-230 of 404) with videos related to

Sort By:
Pageof 41
Clinical Microbiology Reviews|June 13, 2025
Bacterial and fungal infections in persons who inject drugsJeffrey Masters, David Goodman-Meza, Danielle Russell, et al.
European Journal of Gastroenterology & Hepatology|July 23, 2014
Delivery of treatment for hepatitis C virus infection in the primary care settingDavid Baker, Maryam Alavi, Amanda Erratt, et al.
AIDS (London, England)|August 24, 2012
Estimating the cost-effectiveness of needle-syringe programs in AustraliaJisoo A Kwon, Jonathan Anderson, Cliff C Kerr, et al.
Frontiers in Neurology|May 17, 2024
Blood brain barrier disruption and glutamatergic excitotoxicity in post-acute sequelae of SARS COV-2 infection cognitive impairment: potential biomarkers and a window into pathogenesisJoga Chaganti, Govinda Poudel, Lucette Adeline Cysique, et al.
Drug and Alcohol Review|August 9, 2023
Evaluating the prevalence of current hepatitis C infection and treatment among Aboriginal and Torres Strait Islander peoples who inject drugs in Australia: The ETHOS engage studySteven Hobday, Heather Valerio, Troy Combo, et al.
Hepatology (Baltimore, Md.)|October 28, 2011
Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infectionJason Grebely, Son Truong Pham, Gail V Matthews, et al.
Plos One|April 18, 2013
Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individualsGail V Matthews, Rachel J Ali, Anchalee Avihingsanon, et al.
Hepatology (Baltimore, Md.)|April 5, 2013
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antiviralsNatasha K Martin, Peter Vickerman, Jason Grebely, et al.
Plos One|November 27, 2013
Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infectionJordan J Feld, Jason Grebely, Gail V Matthews, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|June 23, 2023
Health-related quality of life among people who inject drugs in AustraliaQinglu Cheng, Sahar Bajis, Evan Cunningham, et al.
Pageof 41